drugset
drugset / Trial / NCT05961111

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

NCT05961111 ↗

Phase 0 Unknown 20 enrolled Shanghai Yunying Medical Technology Linyi People's Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Timeline

Start
2023-06-24
Primary completion
2025-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject R130 Unknown 1 ml Other
Subject R130 Unknown 2 ml Other

Indications

brain cancer breast cancer carcinoma digestive system cancer female reproductive organ cancer head and neck cancer kidney cancer lung cancer melanoma sarcoma